Interagency Communication On Trial Designs Urged At FDA/NIH Stakeholder Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
New FDA/NIH council co-chaired by FDA Commissioner Hamburg and NIH Director Collins includes six additional members from each agency.
You may also be interested in...
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
NIH Rare Diseases Project Could Have Broad Effect On Personalized Medicine
In a high profile effort to speed along personalized medicine, the heads of the National Institutes of Health and FDA are pointing out the possible commercial applications of seemingly small steps, such as the potential for an NIH initiative to accelerate development of therapies for rare diseases to advance personalized medicine in more common illnesses